Weight loss stabilizes after 12 to 18 months, but insulin sensitivity, blood sugar control, blood pressure, and lipid levels remain improved
Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetesrandomized controlled trial
& Majumdar, S
By promoting insulin release and inhibiting glucagon secretion, GLP-1 agonists effectively lower blood sugar levels, providing a valuable therapeutic option for individuals with type 2 diabetes
Additionally, they may impact the brains satiety centers and alter food preferences, encouraging healthier eating patterns
Who GLP-1 weight loss is for - and who it isn't Patients we typically work with on GLP-1 weight management: Adults with BMI 30+ (obesity) who have not achieved sustained weight loss with lifestyle change alone Adults with BMI 27+ and weight-related comorbidities - type 2 diabetes, hypertension, dyslipidemia, sleep apnea, prediabetes, fatty liver disease Patients with insulin resistance or metabolic syndrome where the metabolic and weight pictures are intertwined Patients post-bariatric surgery with weight regain, where appropriate and coordinated with their surgical team GLP-1 medications are not appropriate for patients with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, severe gastroparesis, or active eating disorders
